nach oben

Journal of Neural Transmission

Erschienen in:

01.03.2015 | Psychiatry and Preclinical Psychiatric Studies - Review article

A molecular pathway analysis of the glutamatergic–monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment

verfasst von: Antonio Drago, Enrico Cocchi, Concetta Crisafulli, Alessandro Serretti

Erschienen in: Journal of Neural Transmission | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

The efficacy of current antidepressant (AD) drugs for the treatment of major depressive disorder (MDD) lays behind expectations. The correct genetic differentiation between severe and less severe cases before treatment may pave the way to the most correct clinical choices in clinical practice. Genetics may pave the way such identification, which in turns may provide perspectives for the synthesis of new ADs by correcting the molecular unbalances that differentiate severe and less severe depressive patients. We investigated 1,903 MDD patients from the STAR*D study. Outcome was the number of severe depressive records, defined as a Quick Inventory of Depressive Symptomatology (QIDS)-Clinician rated (C) total score >15, corrected for the number of observations for each patient during the first 14 weeks of citalopram treatment. Predictors were the genetic variations harbored by genes involved in the glutamatergic–monoaminergic interplay as defined in a previous work published by our group. Clinical and socio-demographic stratification factor analyses were taken in cases and controls. Covariated linear regression was the statistical model for the analysis. SNPs were analyzed in groups (molecular pathway analysis) testing the hypothesis that the distribution of significant (p < 0.05) associations between SNPs and the outcome segregates within each pathway/gene subset. The best associated results are relative to two signle SNPs, (rs7744492 in AKAP12 p = 0.0004 and rs17046113 in CAMK2D p = 0.0006) and a molecular pathway (cAMP biosynthetic process p = 0.005). After correction for multitesting, none of them resulted to be significantly associated. These results are consistent with previous findings in literature and further stress that the molecular mechanisms targeted by current ADs may not be the key biological variables that differentiate severe from mild depression.

Nur mit Berechtigung zugänglich

Andrade L, Caraveo-anduaga JJ, Berglund P, Bijl RV, Graaf RD, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kiliç C, Offord D, Bedirhan Ustun T, Wittchen H-U (2003) The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J Methods Psychiatr Res 12:3–21. doi:10.1002/mpr.138 CrossRefPubMed

Arranz MJ, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34:1130–1144. doi:10.1093/schbul/sbn114 CrossRefPubMedCentralPubMed

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354. doi:10.1016/S0006-3223(99)00230-9 CrossRefPubMed

Cheng ATA (2000) Psychosocial and psychiatric risk factors for suicide: Case–control psychological autopsy study. Br J Psychiatry 177:360–365. doi:10.1192/bjp.177.4.360 CrossRefPubMed

Choi YK, Kim K-W (2008) AKAP12 in astrocytes induces barrier functions in human endothelial cells through protein kinase Czeta. FEBS J 275:2338–2353. doi:10.1111/j.1742-4658.2008.06387.x CrossRefPubMed

Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA (2002) cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci Off J Soc Neurosci 22:3262–3268

Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, Martínez-García O, Pardo-García G, Vázquez-Barquero JL (2007) Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 41:659–666. doi:10.1016/j.jpsychires.2006.05.002 CrossRefPubMed

De Leon J, Armstrong SC, Cozza KL (2005) The dosing of atypical antipsychotics. Psychosomatics 46:262–273. doi:10.1176/appi.psy.46.3.262 CrossRefPubMed

Dinieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E, Neve RL, Nestler EJ, Carlezon WA Jr (2009) Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci Off J Soc Neurosci 29:1855–1859. doi:10.1523/JNEUROSCI.5104-08.2009 CrossRef

Drago A, Serretti A (2011) Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR*D study and an independent trial. J Clin Psychopharmacol. doi:10.1097/JCP.0b013e3182189c64 PubMed

Drago A, Crisafulli C, Sidoti A, Serretti A (2011) The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol 94:418–460. doi:10.1016/j.pneurobio.2011.05.009 CrossRefPubMed

Dwivedi Y, Rizavi HS, Shukla PK, Lyons J, Faludi G, Palkovits M, Sarosi A, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2004) Protein kinase a in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol Psychiatry 55:234–243. doi:10.1016/j.biopsych.2003.11.003 CrossRefPubMed

Emsley R, Rabinowitz J, Medori R (2007) Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 89:129–139. doi:10.1016/j.schres.2006.09.013 CrossRefPubMed

Flockhart D (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine

Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP (2005) Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol 20:199–205. doi:10.1097/00004850-200507000-00002 CrossRefPubMed

Goforth HW, Holsinger T (2007) Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT 23:23–25. doi:10.1097/01.yct.0000263257.44539.23 CrossRefPubMed

Gunduz-Bruce H (2005) Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry 162:1966–1969. doi:10.1176/appi.ajp.162.10.1966 CrossRefPubMed

Hirschfeld RMA, Russell JM, Delgado PL, Fawcett J, Friedman RA, Harrison WM, Koran LM, Miller IW, Thase ME, Howland RH, Connolly MA, Miceli RJ (1998) Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 59:669–675. doi:10.4088/JCP.v59n1205 CrossRefPubMed

Inestrosa NC, Arenas E (2010) Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11:77–86. doi:10.1038/nrn2755 CrossRefPubMed

Joober R, Rouleau GA, Lal S, Bloom D, Lalonde P, Labelle A, Benkelfat C (2005) Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res 77:35–41. doi:10.1016/j.schres.2005.01.008 CrossRefPubMed

Jurado S, Biou V, Malenka RC (2010) A calcineurin/AKAP complex is required for NMDA receptor-dependent long-term depression. Nat Neurosci 13:1053–1055. doi:10.1038/nn.2613 CrossRefPubMedCentralPubMed

Kessler RC, Birnbaum HG, Shahly V, Bromet E, Hwang I, McLaughlin KA, Sampson N, Andrade LH, de Girolamo G, Demyttenaere K, Haro JM, Karam AN, Kostyuchenko S, Kovess V, Lara C, Levinson D, Matschinger H, Nakane Y, Browne MO, Ormel J, Posada-Villa J, Sagar R, Stein DJ (2010) Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative. Depress Anxiety 27:351–364. doi:10.1002/da.20634 CrossRefPubMedCentralPubMed

Kudoh A, Takahira Y, Katagai H, Takazawa T (2002) Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 95:114–118. doi:10.1097/00000539-200207000-00020 CrossRefPubMed

Kuo H-W, Liu SC, Tsou H–H, Liu S-W, Lin K-M, Lu S-C, Hsiao M-C, Hsiao C-F, Liu C-Y, Chen C-H, Lu M-L, Shen WW, Tang H-S, Liu S-I, Chang L-H, Wu H-Y, Chang Y-S, Yeh T-K, Chen AC, Liu Y-L (2013) CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics 14:1191–1201. doi:10.2217/pgs.13.105 CrossRefPubMed

Lejeune F, Gobert A, Rivet J-M, Mark JM (1994) Blockade of transmission at NMDA receptors facilitates the electrical and synthetic activity of ascending serotoninergic neurones. Brain Res 656:427–431. doi:10.1016/0006-8993(94)91490-7 CrossRefPubMed

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223. doi:10.1056/NEJMoa051688 CrossRefPubMed

McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E (2010) The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 15:237–249. doi:10.1038/mp.2009.80 CrossRefPubMedCentralPubMed

McGrath P (2006) Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 163:1542. doi:10.1176/appi.ajp.163.9.1542 CrossRefPubMed

Montminy M (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66:807–822. doi:10.1146/annurev.biochem.66.1.807 CrossRefPubMed

Morishita S, Arita S (2003) Possible predictors of response to fluvoxamine for depression. Hum Psychopharmacol 18:197–200. doi:10.1002/hup.469 CrossRefPubMed

Muñoz FJ, Godoy JA, Cerpa W, Poblete IM, Huidobro-Toro JP, Inestrosa NC (2014) Wnt-5a increases NO and modulates NMDA receptor in rat hippocampal neurons. Biochem Biophys Res Commun 444:189–194. doi:10.1016/j.bbrc.2014.01.031 CrossRefPubMed

Nibuya M, Nestler EJ, Duman RS (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci Off J Soc Neurosci 16:2365–2372

Pallotta M, Segieth J, Whitton PS (1998) N-Methyl-d-aspartate receptors regulate 5-HT release in the raphe nuclei and frontal cortex of freely moving rats: differential role of 5-HT1A autoreceptors. Brain Res 783:173–178. doi:10.1016/S0006-8993(97)01333-4 CrossRefPubMed

Perkins D (2004) Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 185:18–24. doi:10.1192/bjp.185.1.18 CrossRefPubMed

Perlis RH, Alpert J, Nierenberg AA, Mischoulon D, Yeung A, Rosenbaum JF, Fava M (2003) Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand 108:432–438. doi:10.1046/j.0001-690X.2003.00168.x CrossRefPubMed

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575. doi:10.1086/519795 CrossRefPubMedCentralPubMed

R Foundation for Statistical Computing (2011) R: A language and environment for statistical computing

Reierson GW, Guo S, Mastronardi C, Licinio J, Wong M-L (2011) cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. Curr Neuropharmacol 9:715–727. doi:10.2174/157015911798376271 CrossRefPubMedCentralPubMed

Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241. doi:10.1001/archpsyc.56.3.241 CrossRefPubMed

Ruhé HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12:331–359. doi:10.1038/sj.mp.4001949 CrossRefPubMed

Rush A (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D Report. Am J Psychiatry 163:1905. doi:10.1176/appi.ajp.163.11.1905 CrossRefPubMed

Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003) The 16-Item Quick Inventory Of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573–583. doi:10.1016/S0006-3223(02)01866-8 CrossRefPubMed

Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G, STAR*D Investigators Group (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142. doi:10.1016/S0197-2456(03)00112-0 CrossRefPubMed

Schulz R, Drayer RA, Rollman BL (2002) Depression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry 52:205–225CrossRefPubMed

Semiz UB, Cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A (2007) Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31:1330–1336. doi:10.1016/j.pnpbp.2007.06.002 CrossRefPubMed

Shelton RC, Sanders-Bush E, Manier DH, Lewis DA (2009) Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 158:1406–1415. doi:10.1016/j.neuroscience.2008.11.036 CrossRefPubMed

Shi Y, Yuan Y, Xu Z, Pu M, Wang C, Zhang Y, Liu Z, Wang C, Li L, Zhang Z (2012) Genetic variation in the calcium/calmodulin-dependent protein kinase (CaMK) pathway is associated with antidepressant response in females. J Affect Disord 136:558–566. doi:10.1016/j.jad.2011.10.030 CrossRefPubMed

Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4–22. doi:10.1111/j.1742-7843.2007.00017.x CrossRefPubMed

Stewart RJ, Chen B, Dowlatshahi D, MacQueen GM, Young LT (2001) Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium. Brain Res Bull 55:625–629CrossRefPubMed

Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S, Storm D, Duman RS (2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci Off J Soc Neurosci 20:4030–4036

Trivedi MH (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40. doi:10.1176/appi.ajp.163.1.28 CrossRefPubMed

Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1–10. doi:10.1016/0014-2999(90)90204-J CrossRefPubMed

Usall J, Suarez D, Haro JM (2007) Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res 153:225–231. doi:10.1016/j.psychres.2006.09.016 CrossRefPubMed

Van der Weide J, Steijns LS, van Weelden MJ (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13:169–172. doi:10.1097/01.fpc.0000054065.98065.a0 CrossRefPubMed

Wand GS, Levine MA (1991) Hormonal tolerance to ethanol is associated with decreased expression of the GTP-binding protein, Gs alpha, and adenylyl cyclase activity in ethanol-treated LS mice. Alcohol Clin Exp Res 15:705–710CrossRefPubMed

Titel: A molecular pathway analysis of the glutamatergic–monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment
verfasst von: Antonio Drago
Enrico Cocchi
Concetta Crisafulli
Alessandro Serretti
Publikationsdatum: 01.03.2015
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 3/2015
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-014-1267-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

CLU rs2279590 polymorphism contributes to Alzheimer’s disease susceptibility in Caucasian and Asian populations

The development of the N1 and N2 components in auditory oddball paradigms: a systematic review with narrative analysis and suggested normative values

Attenuation of serotonin-induced itch responses by inhibition of endocannabinoid degradative enzymes, fatty acid amide hydrolase and monoacylglycerol lipase

New evidence for gait abnormalities among Parkinson’s disease patients who suffer from freezing of gait: insights using a body-fixed sensor worn for 3 days

Electrophysiological characteristics of task-specific tremor in 22 instrumentalists